目的 探讨地奥司明联合阿加曲班治疗下肢深静脉血栓的临床疗效。方法 选择2021年6月-2022年6月在晋城市人民医院治疗的80例下肢深静脉血栓患者,随机法分为对照组(40例)和治疗组(40例)。对照组静脉注射阿加曲班注射液,10 mg/次加入生理盐水100mL,2h内静脉滴注完毕,2次/d。治疗组患者在对照组基础上口服地奥司明片,2片/次,4次/d。两组患者治疗10 d。观察两组患者临床疗效,比较治疗前后两组患者症状缓解时间,静脉血管再通畅率,血清因子肿瘤坏死因子-α(TNF-α)、D-二聚体(D-D)、C反应蛋白(CRP)和白细胞介素-6(IL-6)水平,及不良反应。结果 治疗后,治疗组患者临床有效率为97.50%,明显高于对照组(77.51%,P<0.05)。治疗后,治疗组患者症状好转时间均短于对照组(P<0.05)。治疗后,治疗组患者静脉血管再通畅率明显高于对照组(P<0.05)。治疗后,两组血清因子IL-6、D-D、TNF-α、CRP水平明显降低(P<0.05),且治疗后治疗组明显低于对照组(P<0.05)。治疗组不良反应发生率(7.50%)明显低于对照组(22.50%,P<0.05)。结论 地奥司明联合阿加曲班治疗下肢深静脉血栓效果确切,血管再通畅改善明显,显著降低炎性因子含量,且安全有效。

Objective To investigate the clinical efficacy of diosmin combined with argatroban in treatment of lower extremity deep vein thrombosis. Methods Patients (80 cases) with lower extremity deep vein thrombosis in Jincheng People’s Hospital from June 2021 to June 2022 were randomly divided into control (40 cases) and treatment (40 cases) group. Patients in the control group were iv administered with Argatroban Injection, 10 mg/time added into normal saline 100 mL, which was completed within 2 h, twice daily. Patients in the treatment group po administered with Diosmin Tablets on the basis of the control group, 2 tablets/time, four times daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluation was evaluated, the relief time of symptom, the venous recanalization rates，the levels of serum inflammatory factor IL-6, D-D, TNF-α and CRP, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 97.50%, which was significantly higher than that in the control group (77.51%, P＜0.05). After treatment, the time of symptom improvement in the treatment group was shorter than that in the control group (P＜0.05). After treatment, the recanalization rate of venous vessels in the treatment group was significantly higher than that in the control group (P＜0.05). After treatment, the serum levels of IL-6, D-D, TNF-α and CRP in two groups were significantly decreased (P＜0.05), and which in the treatment group were significantly lower than those in the control group (P＜0.05). The incidence of adverse reactions in the treatment group (7.50%) was significantly lower than that in the control group (22.50%, P＜0.05). Conclusion Diosmin combined with argatroban has exact effect in treatment of lower extremity deep vein thrombosis, and the patency of blood vessels is improved obviously, the content of inflammatory factors is significantly reduced, and which is safe and effective.

R914